STAT3 and cholangiocarcinoma: In addition, metformin, the first-line therapy for DM type 2, exerts anti-proliferative and anti-metastatic activities against CCA cells by targeting STAT3 and NF-κB19 and enhancing chemotherapeutic sensitivity of CCA to cisplatin, the standard chemotherapy20.